Mismatch repair deficiency and response to immune checkpoint blockade
V Lee, A Murphy, DT Le, LA Diaz Jr - The oncologist, 2016 - academic.oup.com
More than 1.6 million new cases of cancer will be diagnosed in the US in 2016, resulting in
more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in …
more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in …
Systematic review: brain metastases from colorectal cancer—incidence and patient characteristics
TD Christensen, KLG Spindler, JA Palshof, DL Nielsen - BMC cancer, 2016 - Springer
Background Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However,
the implications for affected patients are severe, and the incidence has been reported to be …
the implications for affected patients are severe, and the incidence has been reported to be …
[HTML][HTML] ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero… - Annals of …, 2016 - Elsevier
Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic
cytotoxicity for BRAF V600E metastatic colorectal cancer, further augmented by irinotecan …
cytotoxicity for BRAF V600E metastatic colorectal cancer, further augmented by irinotecan …
Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
CG Kim, JB Ahn, M Jung, SH Beom, C Kim… - British journal of …, 2016 - nature.com
Background: Among colorectal cancers (CRCs), high-frequency microsatellite instability
(MSI-H) is associated with a better prognosis, compared with low-frequency MSI or …
(MSI-H) is associated with a better prognosis, compared with low-frequency MSI or …
[HTML][HTML] Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
HC Hsu, TK Thiam, YJ Lu, CY Yeh, WS Tsai, JF You… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS
exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers …
exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers …
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic …
Introduction. Right-and left-sided colorectal cancers (CRCs) differ in clinical and molecular
characteristics. Some retrospective analyses suggested that patients with right-sided tumors …
characteristics. Some retrospective analyses suggested that patients with right-sided tumors …
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
Background Clinical trials investigated the potential role of both KRAS and BRAF mutations,
as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical …
as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical …
The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis
Background and Objectives The prognostic impact of primary colorectal cancer (CRC)
location following resection of colorectal liver metastasis (CRLM) remains largely unknown …
location following resection of colorectal liver metastasis (CRLM) remains largely unknown …
[HTML][HTML] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
CL Nigro, V Ricci, D Vivenza, C Granetto… - World journal of …, 2016 - ncbi.nlm.nih.gov
AIM: To reviewing genetic and epigenetic make-up of metastatic colorectal cancers
(mCRCs) addicted to epidermal growth factor receptor (EGFR) signalling. METHODS: The …
(mCRCs) addicted to epidermal growth factor receptor (EGFR) signalling. METHODS: The …